Nicox SA (Euronext Growth Paris: ALCOX) has moved its lead glaucoma asset into formal US regulatory review after the FDA accepted the New Drug Application for NCX 470, or bimatoprost grenod, and established April 30, 2027 as the PDUFA target date. Kowa Pharmaceuticals America, Nicox’s exclusive US licensee, submitted the application on June 30, 2026, and would lead commercialization if the medicine is approved. Nicox would receive an approval milestone and subsequent royalties, giving the French ophthalmology company a potentially recurring revenue stream without building its own US sales organization.
NCX 470 is a once-daily nitric oxide-donating bimatoprost eye drop designed to lower intraocular pressure through two complementary mechanisms. The bimatoprost component uses established prostaglandin-analog biology, while release of nitric oxide is intended to improve aqueous-humor drainage through the conventional trabecular pathway. The NDA is based principally on two large Phase 3 studies, Mont Blanc and Denali, that together evaluated well over 1,300 patients with open-angle glaucoma or ocular hypertension.
Why combine nitric oxide donation with an established prostaglandin mechanism?
Elevated intraocular pressure is one of the most important modifiable risk factors for glaucoma progression. Prostaglandin analogs are widely used because once-daily dosing can lower IOP effectively by increasing aqueous-humor outflow, but many patients still require additional medicines when a single mechanism does not reduce pressure far enough.
NCX 470 attempts to build two pressure-lowering effects into one molecule. Bimatoprost promotes aqueous-humor outflow through established prostaglandin pathways, while nitric oxide activates soluble guanylate cyclase signaling and relaxes elements of the trabecular meshwork and Schlemm’s canal pathway, potentially facilitating conventional aqueous drainage. Nicox’s development rationale is that combining those actions inside one eye drop may produce greater or more consistent IOP reduction without adding another bottle to the patient’s regimen.
That adherence argument matters because glaucoma treatment is often lifelong and asymptomatic until substantial vision has already been lost. Patients therefore have to administer medication every day to prevent an outcome they cannot immediately feel, making treatment complexity a meaningful clinical variable.
What did the 696-patient Denali trial actually demonstrate?
Denali randomized 696 patients across 90 US and Chinese sites to once-daily NCX 470 0.1% or latanoprost 0.005%. The study met its primary objective of showing that NCX 470 was noninferior to latanoprost across six prespecified time-matched IOP measurements at weeks two and six and month three. IOP reductions from baseline ranged from 7.9 to 10.0 mmHg with NCX 470 compared with 7.1 to 9.8 mmHg using latanoprost.
In a prespecified secondary analysis, NCX 470 produced numerically greater reductions at five of six timepoints and statistically greater reductions at three of six, with the maximum difference reaching approximately 0.8 mmHg. The trial did not achieve the predefined overall statistical-superiority criterion, which means the correct interpretation is stronger than simple equivalence at selected timepoints but weaker than a definitive claim that NCX 470 is globally superior to latanoprost.
That nuance is commercially important. Latanoprost is inexpensive, familiar and deeply established. A new branded therapy may need either demonstrably stronger efficacy, meaningfully simpler treatment or usefulness in patients insufficiently controlled on existing therapies to justify its position.
Did Mont Blanc produce a similar result?
Yes. Mont Blanc enrolled 691 patients in a randomized, double-masked Phase 3 design and established noninferiority of NCX 470 against latanoprost. The trial initially included an adaptive dose-selection stage before moving forward with the 0.1% dose.
Replication across two substantial Phase 3 studies matters because IOP varies by time of day, medication washout, measurement conditions and patient characteristics. Consistent results reduce the risk that one favorable trial reflects an unusually cooperative study population or isolated measurement pattern.
The combined programme therefore gave Kowa the efficacy package needed for the NDA even though the commercial differentiation will depend partly on whether clinicians regard the incremental IOP effect as meaningful relative to cost and tolerability.
What safety trade-off emerged in Denali?
Conjunctival hyperemia was the most common adverse event and occurred in 22% of NCX 470 patients compared with 9.2% of those receiving latanoprost. Through the 12-month Denali extension, 10.1% of NCX 470-treated patients discontinued compared with 6.6% receiving latanoprost. Nicox reported no ocular serious adverse events in the NCX 470 group and no treatment-related non-ocular serious adverse events.
Red eye can appear modest compared with systemic drug toxicity, but chronic ophthalmology treatment is highly sensitive to local tolerability because patients administer drops daily for years. A therapy producing visibly greater hyperemia can affect adherence even when the underlying adverse event is not medically serious.
FDA’s review will therefore assess whether any incremental pressure-lowering advantage and the dual-mechanism rationale justify the local tolerability profile across the full NDA dataset.
Why is this regulatory milestone especially important for Nicox rather than Kowa?
Kowa controls US commercialization, while Nicox’s economics are built around milestone payments and royalties. This reduces the capital Nicox needs to deploy into launch infrastructure while preserving participation if NCX 470 develops into a meaningful glaucoma franchise. The company has separately licensed NCX 470 to Ocumension Therapeutics across China and several Asian markets, where an NDA has also been submitted, and a Japanese Phase 3 programme is ongoing.
Nicox is therefore approaching a transition from development-stage asset owner toward royalty-based economics. FDA approval would trigger another milestone and open the path to a US launch targeted for the second half of 2027, but the April PDUFA date is a target rather than a guaranteed approval date.
The broader strategic question is whether NCX 470 can become more than another effective pressure-lowering drop. Latanoprost already provides inexpensive first-line therapy, and combination drops are available when one mechanism proves insufficient. Kowa will need a clear clinical positioning argument around additional pressure reduction, dosing simplicity or patients inadequately controlled on standard prostaglandin therapy.
What will FDA decide by April 30, 2027?
The agency will assess the complete efficacy, safety, chemistry, manufacturing and labeling package rather than simply confirm that two trials reached noninferiority. Particular attention is likely to fall on the reproducibility of pressure reduction, ocular tolerability and the appropriate strength of comparative claims against latanoprost.
Nicox has already solved one of the harder late-stage risks by reproducing its Phase 3 efficacy result. It has also transferred commercial execution to Kowa, reducing the burden of building a US ophthalmology sales force itself.
The remaining uncertainty is whether FDA agrees that the dual nitric oxide and prostaglandin mechanism delivers a benefit-risk profile worthy of approval. If it does, NCX 470 could give glaucoma physicians another once-daily monotherapy option while giving Nicox the recurring royalty stream toward which the company has spent years developing the asset.
